# Survival Prolongation by Rationale Innovative Genomics

> **NCT03386929** · PHASE1,PHASE2 · TERMINATED · sponsor: **Worldwide Innovative Network Association** · enrollment: 15 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic
- Non-small Cell Lung Cancer Stage IIIB

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Axitinib
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03386929
- **Lead sponsor:** Worldwide Innovative Network Association
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-29
- **Primary completion:** 2022-12-29
- **Final completion:** 2022-12-29
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The SPRING trial had to be early terminated at the end of the Phase 1 portion of the study due to the absence of funding necessary for the performance of the Phase 2.
- **Last updated:** 2023-12-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386929, "Survival Prolongation by Rationale Innovative Genomics". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03386929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*